HOME >> MEDICINE >> NEWS
Bacterium present in eyes with 'wet' age-related macular degeneration

p>Most of the new medications either marketed or being developed to treat wet AMD, such as Macugen (EyeTech Pharmaceuticals) and Lucentis (Genetech) block VEGF.

The study comes at a time of great interest in inflammatory mediators of AMD. Over the past seven months, a flurry of high-impact papers have shown, in aggregate, that nearly 50 percent of AMD can be explained by variations in a gene called Complement Factor H (CFH). This gene makes a protein that regulates the immune and inflammatory responses of the body.

"Our hypothesis is that C. pneumoniae may be the key link between CFH and AMD," Kalayoglu said. "That is, patients with CFH variations may be particularly susceptible to the damaging effects of chronic infection, and an infectious organism like C. pneumoniae may be particularly effective in accelerating inflammation and driving progression of AMD in these patients."

Kalayoglu and colleagues are currently collaborating with CFH researchers to study this hypothesis. "It may be possible to stop or reverse progression of AMD by identifying susceptible patients by diagnostic testing, and then treating these susceptible patients. Although C. pneumoniae is a bacterium that might respond to some antibiotics, much more work needs to be done before considering antibiotic therapy for AMD," he said.

"This is an important study suggesting that infection with C. pneumoniae may be a critical link between a genetic predisposition to AMD and actual progression to disease," said Gerald I. Byrne, Ph.D., professor and chairman of the Department of Molecular Sciences University of Tennessee Health Sciences Center. "This is yet another example of how an infection may unexpectedly contribute to a chronic disease. Certainly the association of C. pneumoniae with heart disease sets the stage for this pathogen's involvement in other chronic conditions. This work is, in some ways, reminiscent of studies done more than 15 years ago on infections and
'"/>

Contact: Mary E. Leach
mary_leach@meei.harvard.edu
617-573-4170
Harvard Medical School
7-Nov-2005


Page: 1 2 3

Related medicine news :

1. RAND presents first Victor Fuchs Research Award to economists at Carnegie Mellon University
2. Cedars-Sinai researchers present new endocrine findings at 2 international conferences
3. Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
4. NY-Presbyterian Hospital/Columbia University Medical Center doctors present at 2007 AUA Meeting
5. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
6. Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW
7. NYP/Weill Cornell Urologists present at 2007 AUA Conference
8. Data on new vaccine for prostate cancer to be presented
9. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
10. Epidemiology of TB: Updates from CDC studies to be presented at ATS 2007
11. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bacterium present eyes with wet age related macular degeneration

(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
Cached News: